Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly  Settings
ISIS [NASD]
Isis Pharmaceuticals, Inc.
Healthcare | Drug Manufacturers - Other | USA
financial highlights | statements
Index- P/E- EPS (ttm)-0.43 Insider Own0.06% Shs Outstand111.70M Perf Week-1.35%
Market Cap2.28B Forward P/E- EPS next Y-0.84 Insider Trans-37.38% Shs Float110.76M Perf Month-7.99%
Income-43.16M PEG- EPS next Q-0.23 Inst Own78.31% Short Float11.76% Perf Quarter44.30%
Sales122.17M P/S18.64 EPS this Y23.49% Inst Trans8.07% Short Ratio7.94 Perf Half Y129.62%
Book/sh1.95 P/B10.46 EPS next Y-10.50% ROA-8.43% Target Price16.83 Perf Year127.82%
Cash/sh3.73 P/C5.46 EPS next 5Y30.00% ROE-24.52% 52W Range7.56 - 23.03 Perf YTD95.31%
Dividend- P/FCF- EPS past 5Y0.00% ROI-9.68% 52W High-11.46% Beta1.07
Dividend %- Quick Ratio6.06 Sales past 5Y11.83% Gross Margin-29.24% 52W Low169.71% ATR0.87
Employees288 Current Ratio6.14 Sales Q/Q86.62% Oper. Margin-43.88% RSI (14)51.07 Volatility4.01% 3.89%
OptionableYes Debt/Eq1.13 EPS Q/Q93.15% Profit Margin-35.32% Rel Volume0.87 Prev Close20.39
ShortableYes LT Debt/Eq1.11 EarningsMay 07 BMO Payout- Avg Volume1.64M Price20.39
Recom2.60 SMA20-3.02% SMA505.24% SMA20044.48% Volume0 Change0.00%
21-Mar-13Reiterated Needham Buy $18 → $20
30-Jan-13Reiterated Needham Buy $14 → $18
17-Oct-12Downgrade Summer Street Research Buy → Neutral
30-Jul-12Reiterated Stifel Nicolaus Buy $11 → $17
22-May-12Initiated Needham Buy $14
26-Mar-12Initiated Canaccord Genuity Hold $10
05-Aug-10Downgrade MP Advisors Outperform → Market Perform $15 → $10
05-Aug-10Downgrade Collins Stewart Buy → Hold
06-Apr-10Initiated Auriga U.S.A Hold $11
18-Nov-09Reiterated Jefferies & Co Buy $19 → $14
29-Jul-09Initiated Cantor Fitzgerald Buy $28
20-Mar-09Reiterated Collins Stewart Buy $17 → $20
10-Feb-09Initiated Citigroup Hold $16
09-Jan-09Initiated Morgan Joseph Buy $18
16-Dec-08Initiated Collins Stewart Buy $17
08-Aug-08Upgrade Needham Hold → Buy $22
09-May-08Upgrade Boenning & Scattergood Market Underperform → Market Perform $12
25-Apr-08Downgrade Boenning & Scattergood Market Outperform → Market Underperform $26 → $12
18-Apr-08Downgrade Leerink Swann Outperform → Mkt Perform $25 → $14
01-Feb-08Reiterated Boenning & Scattergood Market Outperform $32 → $26
23-May-13 07:00AM  Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference PR Newswire
22-May-13 06:29AM  Aegerion's Pricing Power Sends Shares Flying at Seeking Alpha
20-May-13 12:07PM  Isis Pharmaceuticals' Management Presents at UBS Global Healthcare Conference (Transcript) at Seeking Alpha
17-May-13 09:12AM  Presentation Pandemonium Equals 30% Pop at Motley Fool
16-May-13 03:25PM  A Disconnect Between Future Prospects of Drug Candidates Versus Where Share Price is Currently Trading: Portfolio Manager Finny Kuruvilla Discusses the Biotech and Pharmaceutical Sectors Wall Street Transcript
07:51AM  The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals Zacks
15-May-13 06:26PM  ISIS Pharmaceuticals Management Presents at Bank of America Merrill Lynch Health Care Conference (Transcript) at Seeking Alpha
05:00PM  Sanofi/REGN Commence Enrollment Zacks
14-May-13 03:30PM  Isis Gets $3.5M Milestone Payment Zacks
01:04PM  ISIS PHARMACEUTICALS INC Financials EDGAR Online Financials
12:13PM  Celgene Attains 52-Week High Zacks
13-May-13 07:00AM  Isis Pharmaceuticals to Present at the 2013 UBS Global Healthcare Conference PR Newswire
12-May-13 02:41PM  1 Biotech's Surprise Dilution Decoded at Motley Fool
10-May-13 05:15PM  3 Horrendous Health-Care Stocks This Week at Motley Fool
02:57PM  6 Superstars For Your Biotech Portfolio: John McCamant at Seeking Alpha
10:18AM  Snag ISIS Even Lower Than Its Secondary? at Forbes
09-May-13 04:34PM  InPlay: ISIS Pharm earns $3.5 mln from Biogen Idec Briefing.com -5.90%
04:34PM  Isis Pharmaceuticals Earns $3.5 Million from Biogen Idec PR Newswire
02:39PM  Isis Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference PR Newswire
02:36PM  Isis Pharmaceuticals Slides A Little Despite Strong Earnings at Seeking Alpha
01:21PM  Nasdaq stocks posting largest percentage decreases AP
11:28AM  Wal-Marts Pledge to Food Safety, Citibank and Deutsche Bank Duke It Out, and 2 Other Hot Stocks at Wall St. Cheat Sheet
09:30AM  ISIS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
08-May-13 09:50PM  Isis Pharmaceuticals Prices Public Offering Of Common Stock PR Newswire -10.23%
06:04PM  Nasdaq stocks posting largest percentage decreases AP
05:45PM  Isis Reports In-Line Loss Zacks
04:25PM  Isis Stock Falls On Unusually High Volume (ISIS) at TheStreet
01:25AM  Isis Pharmaceuticals's CEO Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha
07-May-13 05:16PM  Isis Initiates ISIS-STAT3 Study Zacks
04:09PM  InPlay: ISIS Pharm announces proposed public offering of 9 million shares of its common stock Briefing.com
04:08PM  Isis Pharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire
04:05PM  Isis Reports Financial Results and Highlights for First Quarter 2013 PR Newswire
09:16AM  ISIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
08:58AM  ISIS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
07:07AM  Q1 2013 Isis Pharmaceuticals Earnings Release - Before Market Open CCBN
06-May-13 04:00PM  Positive Opinion on Allergan Candidate Zacks
02:50PM  Acorda Incurs Loss, Maintains Guidance Zacks
12:28PM  Ford Plays Cautious in Asia, Isis and AstraZeneca Commence Trials, and 3 Other Hot Stocks at Wall St. Cheat Sheet
07:00AM  Isis Pharmaceuticals Announces the Initiation of a Clinical Study of ISIS-STAT3 Rx in Patients with Liver Cancer PR Newswire
04-May-13 11:30AM  3 Booming Biotech Companies at Motley Fool
03-May-13 10:30AM  Isis Reaches New 52-Week High (ISIS) at TheStreet
02-May-13 12:58PM  Webcast Alert: Isis Pharmaceuticals' First Quarter 2013 Financial Results Conference Call PR Newswire
11:11AM  Alternative Generic Drug Products to Sustain Decent Margins and Cash Flow Generation Over the Long Term: Expert Analyst David Amsellem Discusses the Generic Drug Space with The Wall Street Transcript Wall Street Transcript
01-May-13 06:11PM  3 Investment Ideas for Biotech Investors at Motley Fool
30-Apr-13 02:21PM  What News Will Drive Amgen Stock Next? at Motley Fool
29-Apr-13 08:08PM  Wall Street Gets It Backward On Amgen Cholesterol Drug at Forbes
25-Apr-13 08:44AM  In Moribund Cholesterol Field, A New Drug Emerges at Forbes
08:44AM  As Companies Abandon Cholesterol, An Old Player Re-Emerges at Forbes
24-Apr-13 05:40PM  [video] Isis Takes on Huntington's Disease at CNBC
04:40PM  Isis Pharma's ISIS-SMNRx Progresses Zacks
01:31PM  2 Orphan Drugmakers With Upcoming Catalysts at Motley Fool
10:32AM  1 Retailer, 1 Biotech And 1 Management Services Company With Recent Intensive Insider Selling at Seeking Alpha
09:13AM  Overstock.com Part-Owner Sells More Than 132K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
23-Apr-13 12:37PM  Nokia Wins in Court, Bad News for Yum, and 3 Hot Stocks to Watch at Wall St. Cheat Sheet
07:18AM  Isis Pharmaceuticals initiates clinical study of ISIS-SMN Rx in infants with SMA theflyonthewall.com
07:00AM  ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy PR Newswire
22-Apr-13 05:13PM  Isis Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference PR Newswire
03:58PM  4 Healthcare Stock Stories To Kick Off the Trading Week at Wall St. Cheat Sheet
10:45AM  10 Ways NASCAR Can Teach Us How to Invest Better: Part 2 at Motley Fool
19-Apr-13 09:59AM  Isis Stock Hits New 52-Week High (ISIS) at TheStreet +8.71%
16-Apr-13 08:37PM  These Cutting-Edge Science Stocks Are Soaring at Motley Fool
06:46PM  Powerful Cholesterol-Lowering Drugs on Their Way at Motley Fool
04:48PM  Isis Pharmaceuticals Larger Than S&P 500 Component Advanced Micro Devices at Forbes
15-Apr-13 04:12AM  5 Biotechnology Stocks That Greatly Outperformed The Market In Q1 at Seeking Alpha
12-Apr-13 04:24PM  Is RNA Drug Development Coming of Age? at Motley Fool
03:40PM  Isis Pharmaceuticals - Antisense Making Sense at Seeking Alpha
08:42AM  Home Depot Opposes Plastic Settlement and 2 Stocks at 52-Week Highs at Wall St. Cheat Sheet
08-Apr-13 06:29PM  Roche, Isis Pharmaceuticals to Develop Huntington's Disease Treatments at Motley Fool
05:25PM  ISIS Initiates ISIS-APOA Study Zacks
03:25PM  Isis: Big Pharma's Little Friend at Motley Fool
11:01AM  Roche to use Isis's technology to develop brain disorder drug at Reuters
09:03AM  InPlay: ISIS Pharm: Roche and Isis Pharmaceuticals form alliance for Huntington's disease; Roche will make an upfront payment of $30 million to Isis Briefing.com
09:00AM  Roche and Isis Pharmaceuticals form alliance for Huntington's disease PR Newswire
07:27AM  ISIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exh EDGAR Online
04-Apr-13 08:46AM  Jim Cramer: Buy ConAgra, Kimco Realty, and These 2 Stocks at Wall St. Cheat Sheet
03:02AM  Preserving Its Strategic Partnerships Will Be A Key Catalyst For Isis Pharmaceuticals In 2013 at Seeking Alpha
03-Apr-13 08:12PM  Cramer's 'Mad Money' Recap: Risk vs. Reward at TheStreet
07:10PM  Cramer Highlights Biotech 'Game Changers' at CNBC
06:25PM  [video] Cramer on Game-Changing Health Stocks at CNBC
03:57PM  4 Healthcare Stock Stories For Midweek Perusal at Wall St. Cheat Sheet
07:38AM  Zacks Bull and Bear of the Day Highlights: Apollo Global Management, Agnico-Eagle Mines, Isis Pharmaceuticals, GlaxoSmithKline and Sanofi Zacks
07:02AM  Isis Pharmaceuticals initiates Phase 1 study of ISIS-APOARx theflyonthewall.com
07:00AM  Isis Initiates Phase 1 Study of ISIS-APOA Rx to Treat Atherosclerosis PR Newswire
02-Apr-13 03:58PM  Isis Publishes Encouraging Data Zacks
01-Apr-13 07:02AM  InPlay: ISIS Pharm publishes data demonstrating antisense targeting of ApoC-III significantly reduces ApoC-III and Triglycerides Briefing.com
07:00AM  Isis Publishes Data Demonstrating Antisense Targeting of ApoC-III Significantly Reduces ApoC-III and Triglycerides PR Newswire
29-Mar-13 04:57AM  Biotech: Hedging While Speculating at Seeking Alpha
28-Mar-13 10:40AM  Should AstraZeneca and Bristol-Myers Squibb Get Married? at Motley Fool
05:45AM  AstraZeneca CEO Chases Multiple Strands in RNA Drug Quest at Bloomberg
27-Mar-13 08:01PM  AstraZeneca CEO Chases Multiple Strands in RNA Drug Quest at Bloomberg
25-Mar-13 04:08PM  CHMP Still Negative on Isis' Kynamro Zacks
24-Mar-13 04:30AM  Solving The R&D Investment Dilemma With Project Funding: Mark Kessel at Seeking Alpha
22-Mar-13 05:48PM  4 Healthcare Stock Stories To Close the Trading Week at Wall St. Cheat Sheet -6.34%
05:08PM  EU Deja Vu for This Biotechs Orphan Drug at Motley Fool
02:31PM  InPlay: ISIS Pharm provides update on CHMP opinion on KYNAMRO (mipomersen); CHMP has maintained a negative opinion regarding the marketing authorization application for KYNAMRO Briefing.com
02:30PM  Isis Provides Update on CHMP Opinion on KYNAMRO (mipomersen) PR Newswire
11:12AM  Sanofi Obtains EU Panel Recommendation for MS Tablet Aubagio at Bloomberg
10:51AM  Europe and US Diverge On Two New Drugs at Forbes
21-Mar-13 09:56PM  Isis Pharmaceuticals' CEO Discusses the ISIS-SMN Rx Phase 1 data presented at the 2013 AAN Annual Meeting (Transcript) at Seeking Alpha
06:30PM  3 Ways You Can Be a Successful Biotech Investor at Motley Fool
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company's flagship product, KYNAMRO injection, is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia for the reduction of low-density lipoprotein cholesterol. It also has a pipeline of 28 drugs in development for the treatment of cardiovascular, severe and rare, neurologic, and metabolic diseases, as well as cancer. The company has collaboration agreements with AstraZeneca to discover and develop antisense drugs against five cancer targets; Biogen Idec to develop and commercialize ISIS-SMNRx for the treatment of spinal muscular atrophy; and Bristol-Myers Squibb to discover, develop, and commercialize antisense drugs targeting proprotein convertase subtilisin/kexin type 9. In addition, it has strategic alliances with Eli Lilly and Company for the development of LY2275796, an antisense inhibitor of eIF-4E; Genzyme Corporation for the licensing and co-development of KYNAMRO; and GlaxoSmithKline to develop drugs against targets for rare and serious diseases, including infectious diseases and conditions causing blindness. Isis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BENNETT C FRANKSVP, Antisense ResearchMay 01Option Exercise7.6929,945230,41025,910May 02 07:48 PM
BENNETT C FRANKSVP, Antisense ResearchMay 01Sale22.2629,945666,6062,110May 02 07:48 PM
BENNETT C FRANKSVP, Antisense ResearchApr 30Option Exercise11.1230,000333,60032,110May 02 07:48 PM
BENNETT C FRANKSVP, Antisense ResearchApr 30Sale22.5130,000675,1532,110May 02 07:48 PM
PARSHALL B LYNNECOO, SecretaryApr 25Option Exercise8.0525,854208,19221,341Apr 26 07:06 PM
PARSHALL B LYNNECOO, SecretaryApr 25Sale22.5025,854581,5862,941Apr 26 07:06 PM
PARSHALL B LYNNECOO, SecretaryApr 24Option Exercise11.1230,000333,60032,941Apr 26 07:06 PM
CROOKE STANLEY TChairman, CEO and PresidentApr 24Sale22.1210,000221,200825,391Apr 26 07:01 PM
PARSHALL B LYNNECOO, SecretaryApr 24Sale22.1230,000663,6002,941Apr 26 07:06 PM
PARSHALL B LYNNECOO, SecretaryApr 23Option Exercise11.1210,000111,20012,941Apr 23 08:48 PM
PARSHALL B LYNNECOO, SecretaryApr 23Option Exercise6.8120,000136,20010,000Apr 23 08:48 PM
O'NEIL PATRICK R.SVP, Legal & General CounselApr 23Option Exercise13.2227,320361,10111,984Apr 23 09:04 PM
CROOKE STANLEY TChairman, CEO and PresidentApr 23Sale22.1030,000662,901835,391Apr 23 08:46 PM
PARSHALL B LYNNECOO, SecretaryApr 23Sale22.1010,000220,9672,941Apr 23 08:48 PM
PARSHALL B LYNNECOO, SecretaryApr 23Sale22.1020,000441,9340Apr 23 08:48 PM
O'NEIL PATRICK R.SVP, Legal & General CounselApr 23Sale22.1327,320604,5921,324Apr 23 09:04 PM
HOUGEN ELIZABETH LSVP, Finance & CFOApr 22Option Exercise14.8717,656262,59210,143Apr 23 08:45 PM
CROOKE STANLEY TChairman, CEO and PresidentApr 22Option Exercise7.2620,000145,20021,661Apr 23 08:46 PM
Monia Brett PSVP, Antisense Drug DiscoveryApr 22Option Exercise11.1217,000189,04022,695Apr 23 08:47 PM
PARSHALL B LYNNECOO, SecretaryApr 22Option Exercise11.1230,000333,60032,941Apr 23 08:48 PM
HOUGEN ELIZABETH LSVP, Finance & CFOApr 22Sale21.4617,656378,814300Apr 23 08:45 PM
CROOKE STANLEY TChairman, CEO and PresidentApr 22Sale20.9920,000419,8001,661Apr 23 08:46 PM
CROOKE STANLEY TChairman, CEO and PresidentApr 22Sale20.9910,000209,900865,391Apr 23 08:46 PM
Monia Brett PSVP, Antisense Drug DiscoveryApr 22Sale21.2617,000361,4205,695Apr 23 08:47 PM
PARSHALL B LYNNECOO, SecretaryApr 22Sale20.9930,000629,7002,941Apr 23 08:48 PM
Geary Richard SSVP, DevelopmentApr 19Option Exercise11.122,04222,7076,296Apr 23 08:44 PM
CROOKE STANLEY TChairman, CEO and PresidentApr 19Option Exercise7.2630,000217,80031,661Apr 23 08:46 PM
Monia Brett PSVP, Antisense Drug DiscoveryApr 19Option Exercise11.122,50027,8008,195Apr 23 08:47 PM
PARSHALL B LYNNECOO, SecretaryApr 19Option Exercise7.2630,000217,80032,941Apr 23 08:48 PM
O'NEIL PATRICK R.SVP, Legal & General CounselApr 19Option Exercise14.9415,000224,0407,324Apr 23 09:04 PM
Geary Richard SSVP, DevelopmentApr 19Sale20.802,04242,4744,254Apr 23 08:44 PM
CROOKE STANLEY TChairman, CEO and PresidentApr 19Sale20.0130,000600,1801,661Apr 23 08:46 PM
Monia Brett PSVP, Antisense Drug DiscoveryApr 19Sale21.252,50053,1255,695Apr 23 08:47 PM
PARSHALL B LYNNECOO, SecretaryApr 19Sale20.0130,000600,1802,941Apr 23 08:48 PM
O'NEIL PATRICK R.SVP, Legal & General CounselApr 19Sale20.3615,000305,4361,324Apr 23 09:04 PM
O'NEIL PATRICK R.SVP, Legal and General CounselApr 12Option Exercise14.245,46077,7515,654Apr 15 07:09 PM
O'NEIL PATRICK R.SVP, Legal and General CounselApr 12Sale19.615,460107,0961,324Apr 15 07:09 PM
Geary Richard SSr VP, DevelopmentApr 11Option Exercise11.127,00077,84011,254Apr 15 07:07 PM
Geary Richard SSr VP, DevelopmentApr 11Sale19.527,000136,6404,254Apr 15 07:07 PM
O'NEIL PATRICK R.SVP, Legal and General CounselMar 21Option Exercise14.189,000127,62010,324Mar 22 07:56 PM
Geary Richard SSr VP, DevelopmentMar 21Option Exercise11.121,00011,1205,254Mar 22 07:57 PM
Geary Richard SSr VP, DevelopmentMar 21Sale19.501,00019,5004,254Mar 22 07:57 PM
O'NEIL PATRICK R.SVP, Legal and General CounselMar 21Sale19.269,000173,3401,324Mar 22 07:56 PM
HOUGEN ELIZABETH LSVP, Finance and CFOMar 20Option Exercise11.1214,376159,8619,884Mar 21 08:25 PM
KLEIN JOSEPH IIIDirectorMar 20Option Exercise13.603,92453,3572,500Mar 21 08:25 PM
KLEIN JOSEPH IIIDirectorMar 20Sale18.003,92470,6320Mar 21 08:25 PM
HOUGEN ELIZABETH LSVP, Finance and CFOMar 20Sale18.1314,376260,637300Mar 21 08:25 PM
KLEIN JOSEPH IIIDirectorMar 13Option Exercise5.2020,800108,1446,766Mar 14 09:00 PM
KLEIN JOSEPH IIIDirectorMar 13Sale18.0120,800374,5440Mar 14 09:00 PM
HOUGEN ELIZABETH LSVP, Finance and CFOMar 05Option Exercise6.815,04034,3225,340Mar 07 08:16 PM
Monia Brett PSVP, Antisense Drug DiscoveryMar 05Option Exercise6.8118,240124,21423,935Mar 07 08:16 PM
Monia Brett PSVP, Antisense Drug DiscoveryMar 05Sale16.8618,240307,5995,695Mar 07 08:16 PM
HOUGEN ELIZABETH LSVP, Finance and CFOMar 05Sale16.865,04084,960300Mar 07 08:16 PM
BERTHELSEN SPENCER RDirectorFeb 21Option Exercise5.1710,00051,70039,300Feb 22 07:17 PM
O'NEIL PATRICK R.SVP, Legal & General CounselFeb 19Option Exercise10.291,60016,4642,924Feb 20 07:03 PM
O'NEIL PATRICK R.SVP, Legal & General CounselFeb 19Sale14.801,60023,6801,324Feb 20 07:03 PM
O'NEIL PATRICK R.SVP, Legal & General CounselFeb 15Option Exercise10.293503,6021,574Feb 20 07:03 PM
O'NEIL PATRICK R.SVP, Legal & General CounselFeb 15Sale14.813505,1851,324Feb 20 07:03 PM
O'NEIL PATRICK R.SVP, Legal & General CounselFeb 13Option Exercise7.366,10044,9006,663Feb 14 08:35 PM
O'NEIL PATRICK R.SVP, Legal & General CounselFeb 13Sale14.176,23988,4071,324Feb 14 08:35 PM
O'NEIL PATRICK R.SVP, Legal and General CounselJan 30Option Exercise10.292,00020,5803,463Jan 31 07:57 PM
O'NEIL PATRICK R.SVP, Legal and General CounselJan 30Sale14.822,00029,6401,463Jan 31 07:57 PM
O'NEIL PATRICK R.SVP, Legal and General CounselJan 29Sale13.403004,0201,463Jan 31 07:57 PM
O'NEIL PATRICK R.SVP, Legal & General CounselJan 17Sale14.162423,4271,763Jan 17 08:35 PM
BENNETT C FRANKSVP, Antisense ResearchJan 16Sale14.003094,3262,110Jan 17 08:40 PM
Geary Richard SSVP, DevelopmentJan 16Sale14.003454,8304,254Jan 17 08:40 PM
CROOKE STANLEY TChairman, CEO and PresidentJan 16Sale14.001432,002174Jan 17 08:39 PM
CROOKE STANLEY TChairman, CEO and PresidentJan 16Sale14.001,31718,4381,661Jan 17 08:39 PM
HOUGEN ELIZABETH LSVP, Finance & CFOJan 16Sale14.002423,388300Jan 17 08:37 PM
Monia Brett PSVP, Antisense Drug DiscoveryJan 16Sale14.003304,6205,581Jan 17 08:38 PM
PARSHALL B LYNNECOO, SecretaryJan 16Sale14.0075910,6262,941Jan 17 08:36 PM
BENNETT C FRANKSVP, Antisense ResearchJan 15Option Exercise0.0069502,419Jan 17 08:40 PM
Geary Richard SSVP, DevelopmentJan 15Option Exercise0.0077604,599Jan 17 08:40 PM
CROOKE STANLEY TChairman, CEO and PresidentJan 15Option Exercise0.003170317Jan 17 08:39 PM
CROOKE STANLEY TChairman, CEO and PresidentJan 15Option Exercise0.002,97802,978Jan 17 08:39 PM
HOUGEN ELIZABETH LSVP, Finance & CFOJan 15Option Exercise0.005420542Jan 17 08:37 PM
Monia Brett PSVP, Antisense Drug DiscoveryJan 15Option Exercise0.0073705,816Jan 17 08:38 PM
PARSHALL B LYNNECOO, SecretaryJan 15Option Exercise0.001,71503,700Jan 17 08:36 PM
O'NEIL PATRICK R.SVP, Legal & General CounselJan 15Option Exercise0.0054202,005Jan 17 08:35 PM
O'NEIL PATRICK R.SVP, Legal and General CounselJan 04Sale10.761,29613,9451,463Jan 04 08:00 PM
Monia Brett PVP, Antisense Drug DiscoveryJan 03Sale10.843113,3715,288Jan 03 07:46 PM
Geary Richard SSr VP, DevelopmentJan 03Sale10.842652,8733,823Jan 03 07:44 PM
Geary Richard SSr VP, DevelopmentDec 13Option Exercise5.256,00031,5009,190Dec 17 08:03 PM
Geary Richard SSr VP, DevelopmentDec 13Sale9.636,00057,7513,190Dec 17 08:03 PM
ISIS PHARMACEUTICALS INC10% OwnerOct 10Buy4.00750,0003,000,0007,049,500Oct 11 07:56 PM
CROOKE STANLEY TChairman, CEO and PresidentSep 21Option Exercise6.8429,462201,52029,462Sep 21 07:20 PM
CROOKE STANLEY TChairman, CEO and PresidentSep 21Sale14.0629,462414,2360Sep 21 07:20 PM
CROOKE STANLEY TChairman, CEO and PresidentSep 20Option Exercise6.3430,000190,15520,538Sep 21 07:20 PM
CROOKE STANLEY TChairman, CEO and PresidentSep 20Sale15.019,462142,0060Sep 21 07:20 PM
CROOKE STANLEY TChairman, CEO and PresidentSep 19Option Exercise5.2530,000157,50030,000Sep 21 07:20 PM
CROOKE STANLEY TChairman, CEO and PresidentSep 19Sale14.8230,000444,4500Sep 21 07:20 PM
CROOKE STANLEY TChairman, CEO and PresidentSep 13Option Exercise5.2527,074142,13927,074Sep 17 06:36 PM
CROOKE STANLEY TChairman, CEO and PresidentSep 13Sale14.5527,074393,9270Sep 17 06:36 PM
PARSHALL B LYNNECOO, SecretarySep 07Option Exercise6.8410,00068,4005,000Sep 11 06:31 PM
PARSHALL B LYNNECOO, SecretarySep 07Option Exercise6.842,50617,1414,491Sep 11 06:31 PM
PARSHALL B LYNNECOO, SecretarySep 07Sale15.1210,000151,2000Sep 11 06:31 PM
PARSHALL B LYNNECOO, SecretarySep 07Sale15.122,50637,8911,985Sep 11 06:31 PM
CROOKE STANLEY TChairman, CEO and PresidentSep 06Option Exercise5.4912,61269,2746,000Sep 06 09:38 PM
CROOKE STANLEY TChairman, CEO and PresidentSep 06Option Exercise5.2517,38891,2878,694Sep 06 09:38 PM
Monia Brett PVP, Antisense Drug DiscoverySep 06Option Exercise5.2512,03163,16317,415Sep 06 09:39 PM
open in yahoo | open in reuters | open in google